PUBLIC COMPANY
savePATH
updated 2mo ago
community read0 votes
🐶 often sniffed alongside
top 8- tagRecall10 co-mentions · 10 sources
- tagHematology6 co-mentions · 6 sources
- tagAdCom4 co-mentions · 4 sources
- tag510(k) Clearance3 co-mentions · 3 sources
- companyUniversity of Virginia1 co-mentions · 1 sources
- companyUniversity of Washington1 co-mentions · 1 sources
- tagCardiology1 co-mentions · 1 sources
- tagImmunology1 co-mentions · 1 sources
pipeline
1
marketed
0
phase 3
0
catalysts ytd
8
approvals ytd
0
recalls ytd
6
Pipeline(1)
pipeline depth1 products
1Preclinical
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
- phase2Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
- phase2Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
- phase2Infant Malaria Vaccine Schedule Optimization
- phase3Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls
- phase1Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
- phase2Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy
🐶 Hiring Signal
News
- Capricor soars on potential FDA review extension, filing amendmentsCapricor Therapeutics’ CEO Linda Marbán believes the FDA is willing to work with the biotech as the Aug. 22 deadline approaches for its Duchenne muscular dystrophy cell therapy deramiocel, with the…biospace · 1d ago
- Skye and Redx form new entity with $125M to advance fibrosis assetsSkye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, calle…fiercebiotech · 1d ago
- MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighterDespite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.fiercebiotech · 1d ago
- Nascent US psychedelic therapy opportunity attracts overseas manufacturersCompanies that manufacture MDMA and psilocybin for patients in other countries are looking to use their experience to access the potential U.S. market.biospace · 1d ago
- Ovid and Takeda's epilepsy drug gets new life at Perceptive-backed NewCoAbout 26 months after failing two Phase 3 trials, an epilepsy treatment candidate is getting plucked off biopharma's shelves and will be given a new chance at life. Life sciences investment firm Pe…endpoints · 2d ago
- MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troublesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2d ago
- Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100MThe terms of the agreement with Royalty Pharma suggest the market potential of Zealand Pharma’s polycythemia vera drug candidate may be undervalued, according to Jefferies analysts.biospace · 2d ago
- PDS halts work on phase 3 cancer therapy to focus on colorectal contenderPDS Biotechnology has called a halt to its phase 3 head and neck cancer therapy to channel resources to a drug in phase 2 development for metastatic colorectal cancer.fiercebiotech · 2d ago
- Psychedelics developer Definium scores more positive data for LSD pillResults from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.biopharma_dive · 3d ago
- After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags onAardvark Therapeutics has confirmed it is walking away from recently terminated phase 3 trials, telling investors it has no plans to resume the studies “as previously designed” as it works to find…fiercebiotech · 3d ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that